Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 12% YoY revenue increase and improved margins, driven by demand in medical and defense sectors. Despite risks like economic conditions and potential military spending cuts, the company's operational efficiency and product mix improvements bolster sentiment. The absence of strategic updates or shareholder return plans limits the positivity, but the solid financials suggest a positive short-term stock reaction.
Key Financial Performance
Revenue Ultralife Corporation reported revenue of $35.2 million for Q1 2026, representing a 12% increase year-over-year. This growth was attributed to higher demand in the medical and government/defense sectors.
Gross Margin Gross margin improved to 28.5% in Q1 2026, up from 26.3% in the prior year. The improvement was driven by favorable product mix and operational efficiencies.
Operating Income Operating income was $3.1 million for Q1 2026, a 24% increase compared to the same period last year. This was due to higher revenues and improved gross margins.
Net Income Net income for Q1 2026 was $2.4 million, up 20% year-over-year. The increase was primarily due to higher operating income.
Earnings Per Share (EPS) Earnings per share were $0.15 for Q1 2026, compared to $0.12 in Q1 2025, reflecting a 25% increase. This was driven by improved profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Uncertain Global Economic Conditions: Potential risks from uncertain global economic conditions that could adversely impact the company's performance.
Reductions in Revenues from Key Customers: Risk of reduced revenues from key customers, which could negatively affect financial performance.
Delays or Reductions in Military Spending: Challenges related to potential delays or reductions in U.S. and foreign military spending, impacting revenue streams.
Acceptance of New Products: Risk of limited acceptance of new products on a global basis, which could hinder growth and market expansion.
Supply Chain Disruptions: Potential disruptions or delays in the supply of raw materials and components due to business conditions, global conflicts, weather, or other uncontrollable factors.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO Director
CEO Ultralife
CFO Treasurer
Conference today
Corporate Secretary
Director Philip
EDT day
Fain CFO
Instructions today
Investor News
Manna President
News Investor
Philip Fain
Results Instructions
Secretary EDT
Treasurer Corporate
Ultralife Conference
Ultralife President
Ultralife Results
component condition
condition conflict
conference speaker
day Ultralife
reduction revenue
release copy
revenue delay
speaker today
today Ultralife
today conference
website release
ULBI Transcript
Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights strong financial performance with a 12% YoY revenue increase and improved margins, driven by demand in medical and defense sectors. Despite risks like economic conditions and potential military spending cuts, the company's operational efficiency and product mix improvements bolster sentiment. The absence of strategic updates or shareholder return plans limits the positivity, but the solid financials suggest a positive short-term stock reaction.
Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call highlights a mixed financial performance with strong revenue growth in Battery & Energy Products but significant challenges in Communications Systems. Operational inefficiencies, delays in government contracts, and a net loss due to impairment charges weigh negatively. The Q&A section reveals management's lack of clarity on timelines for key projects, adding uncertainty. Despite some positive aspects like backlog growth and new medical orders, the overall sentiment is negative, especially given the financial losses and strategic risks.
Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Unknown11-18
The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.
Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.
ULBI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
